Zhaoke Ophthalmology (SEHK:6622) Stock Carries A 34.7x P/S Under Heavy Losses

Traders kept Zhaoke Ophthalmology almost flat coming into the H1 2026 report, with the stock up only about 2% over the past week. The calm price action contrasts with a much more charged reality. The company is still posting heavy losses, with H1 basic earnings per share at a loss of ¥0.22 and a net loss of ¥122.6 million.

The key issue is valuation. Zhaoke Ophthalmology trades on a P/S multiple of 34.7x, compared with the Hong Kong pharmaceuticals average near 2x. This puts every line of this loss-making update under close sentiment scrutiny.

Is Zhaoke Ophthalmology really earning a premium P/S multiple, or is sentiment running ahead of the financials? Compare the current share price, revenue base and loss profile against our valuation analysis for Zhaoke Ophthalmology.

H1 2026 Earnings Summary

• Revenue H1 2026 vs. H1 2025: ¥18.828 million vs. ¥15.803 million (change in revenue level between periods)
• Net Loss H1 2026 vs. H1 2025: ¥122.593 million loss vs. ¥116.623 million loss (change in loss level between periods)
• Basic EPS H1 2026 vs. H1 2025: loss of ¥0.22 per share vs. loss of ¥0.21354 per share (change in per share loss between periods)
• Trailing 12-month Net Loss to H1 2026 vs. TTM to H1 2025: ¥214.952 million loss vs. ¥278.314 million loss (lower loss over the trailing period)

Tired of scrolling through paragraphs of figures on Zhaoke Ophthalmology without seeing the full picture? Get a clear visual view of the company, with its valuation front and center, in the interactive company report for Zhaoke Ophthalmology.

Zhaoke Ophthalmology: Testing The Bullish Story

Bulls in Zhaoke Ophthalmology will point to revenue of ¥18.828 million in H1 2026 compared with ¥15.803 million in H1 2025 as a sign that the commercial base is at least moving in the right direction. The trailing 12 month loss of ¥214.952 million is also lower than the ¥278.314 million loss a year earlier. For a pipeline heavy ophthalmology company, that combination of higher sales and a smaller trailing loss helps the multi asset platform story look more grounded than purely aspirational.

Where The Bearish Concerns Still Bite

Bears will focus on the size and persistence of losses. Zhaoke Ophthalmology reported an H1 2026 net loss of ¥122.593 million compared with ¥116.623 million a year earlier, and basic EPS loss widened from ¥0.21354 to ¥0.22. That sits uncomfortably next to a still modest revenue base. Even with an improved trailing loss profile, the latest half shows that funding a broad ophthalmology pipeline continues to weigh heavily on earnings, which keeps execution and financing risk firmly in view for investors.

With Zhaoke Ophthalmology still loss making and trading on a lofty 34.7x P/S multiple, investors need to verify how long current cash and funding routes can support this pipeline. Check the full financial health analysis of Zhaoke Ophthalmology stock.

Stay Ahead Of Your Next Move

If the gap between Zhaoke Ophthalmology's lofty 34.7x P/S multiple and its current loss profile has your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch how the story develops. After you decide to take a position, keep on top of what matters most to your holdings with the Portfolio Command Center that filters out noise and highlights key changes. For a wider view on sentiment around Zhaoke Ophthalmology and other stocks, tap into thousands of investor viewpoints through the Community. Spot potential catalysts and risks early, stay informed, and keep your decisions a step ahead of the market.

Seeking Alternatives Beyond Zhaoke Ophthalmology

Fresh ideas move first. While others stay locked on yesterday's headlines, you can spot under the radar stocks building breakout momentum before the crowd even blinks. Act now.

• Scan for strong cash generators that could fuel the next leg of market momentum with a curated 266 high quality undervalued stocks before they are caught by mainstream screens and headlines.
• Zero in on mission critical suppliers to the AI buildout using the focused 56 AI infrastructure stocks while they are still flying under the radar for now.
• Target companies reinforcing the backbone of tomorrow's energy transition using the hand picked 38 power grid technology and infrastructure stocks while it matters and entry prices have not yet taken off.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com